This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
uman umbilical cord blood-derived msenchymal stem cell (hUCB-MSC) has been regarded as a fascinating candidate of
stem cell therapy in alzheimer?s disease (AD). Recently, we reported that transplantation of hUCB-MSC reduced amyloid
plaques via release of soluble intercellular adhesion molecule-1 in vitro and in vivo. In addition, we observed that a certain
secreted proteins of hUCB-MSC stimulate neurogenesis in a transgenic mice model of AD. These data suggested that secreted
proteins of hUCB-MSC act simultaneously in microenvironment of AD. Based on these findings, we already finished Phase I
clinical trial in Korea. In this presentation, I will briefly introduce our efforts to develop hUCB-MSC therapeutics for AD from
the bench to clinical trial.
Chang has completed his Ph.D in 2005 from Gwangju-Institute of Science & Technology (GIST) and postdoctoral studies from Korea-Institute of
Science & Technology (KIST). Now, he is the director of research division II in R&D Center of MEDIPOST Co., Ltd which is a leading biopharmaceutical
company of cord blood MSC therapeutics in South Korea. He also has been worked as a project manager for phase I clinical trial for AD using hUCB-
MSC. He has published more than 13 papers after 2008 in reputed journals regarding stem cells and serving as an editorial board member of World
Journal of Stem Cells.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals